- CA$130.80m
- CA$170.26m
- $55.50m
Brief: HLS Therapeutics Q4 2018 Revenue Was $16.7 Mln Compared To $20.4 Mln In Q4 2017
Brief: HLS Therapeutics Releases New Data From Vascepa Study
Brief: HLS Therapeutics Licenses And Files 'Athelas One' Point-Of-Care Device
Brief: HLS Therapeutics receives conditional approval to graduate to the Toronto Stock Exchange
Brief: HLS Therapeutics Reports Q3 Loss Per Share Of $0.72
Brief: Hls Therapeutics Appoints Tim Hendrickson As CFO
Brief: HLS Therapeutics Q2 Loss Per Share $0.02
Brief: HLS Therapeutics Enters Into Automatic Share Purchase Plan
Brief: Hls Therapeutics Announces Qtrly Net Loss $0.19 Per Common Share
Brief: HLS Therapeutics Announces Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Fiscal 2017 Financial Results
Brief: Automodular And Hls Receive Shareholder And Court Approval For Plan Of Arrangement
Brief: Automodular And HLS To Amend Arrangement Agreement
Brief: Automodular and HLS Amend Arrangement Agreement
Brief: Automodular Corp Says It Reached Settlement In Its Claim Against General Motors Company And General Motors Of Canada
Brief: Automodular Announces Receipt Of Interim Order For Proposed Transaction With HLS Therapeutics
Brief: Automodular Corp Agrees To A Business Combination With HLS Therapeutics
Brief: Automodular Corp reports qtrly shr loss of C$0.03
Brief: Automodular Corporation qtrly loss per share $0.02